Physician profile
Dmitri Kovalev
NPI 1730675117
$1,354.56
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $11.69 · 2021: $182 · 2022: $42.98 · 2023: $780 · 2024: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $934.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $266.66 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $216.29 | 2023 | Austedo Xr |
| Neurelis, INC. | $155.35 | 2023-2024 | Valtoco |
| Neurocrine Biosciences, INC. | $130.23 | 2023 | Ingrezza, Ongentys |
| Abbvie INC. | $80.93 | 2022-2023 | |
| Acadia Pharmaceuticals INC | $64.49 | 2023 | Nuplazid |
| Pfizer INC. | $58.33 | 2020-2023 | |
| Otsuka America Pharmaceutical, INC. | $49.43 | 2023 | Rexulti |
| Csl Behring | $41.95 | 2021 | |
| Livanova USA, INC. | $37.14 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $34.15 | 2023 | Vyvgart Hytrulo |
| Merz Pharmaceuticals, LLC | $29.11 | 2023 | Xeomin |
| Takeda Pharmaceuticals U.S.A., INC. | $27.51 | 2023 | |
| Kyowa Kirin, INC. | $26.59 | 2023 | Nourianz |
| Genentech USA, INC. | $24.00 | 2023 | Enspryng |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $22.25 | 2019 | |
| Tg Therapeutics, INC. | $19.81 | 2023 | |
| Allergan, INC. | $19.69 | 2021 | |
| Ucb, INC. | $18.96 | 2023 | Briviact |
| Biogen, INC. | $16.80 | 2023 | Tysabri |
| Medtronic USA, INC. | $14.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Kovalev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.